New Two-Target antibody enters human testing for stubborn acne
NCT ID NCT07449156
Summary
This early-stage study is testing a new drug called HB0043 for adults with moderate to severe acne. The drug is a special antibody designed to target two specific inflammation pathways thought to drive acne. Researchers will check if the treatment is safe and if it reduces the number and severity of acne lesions over 16 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACNE VULGARIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatology Hospital affiliated to Shandong First Medical University,
Jinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.